Dublin, July 22, 2020 (GLOBE NEWSWIRE) -- The "Neurological Biomarker Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product; Application; End User; and Geography" report has been added to ResearchAndMarkets.com's offering.
The global neurological biomarker market is expected to reach US$ 5, 501.8 million by 2027 from US$ 14, 454.7 million in 2019; it is estimated to grow at a CAGR of 13.0% from 2020 to 2027.
The rising prevalence of neurological diseases and growing focus on neurological biomarker researchare the major factorsdriving the growth of the neurological biomarker market. However, the concerns associated with biomarker such as measurement errors and cost hindersthe growth of the market.
Neurological diseases contribute to a significant burden on health systems in terms of disease diagnosis, treatment, and management. Epilepsy, Alzheimer's disease, multiple sclerosis, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy are among the major neurological disorders. According to the Global Burden of Disease Study, in 2016, neurological disorders are the main cause of disability-adjusted life-years (DALYs) and the second major cause of deaths. Stroke (42.2%), migraine (16.3%), Alzheimer's, and other dementias (10.4%) are among the four most significant neurological diseases causing DALYs.As per the 2019 Alzheimer's disease Facts and Figures Report, in 2019, ~5.8 million Americans of all ages were suffering from Alzheimer's dementia. Among 5.8 million patients, 81% of the patients were aged 75 years and above. Thus, the increasing prevalence of neurological diseases is a major factor driving the growth of the global neurological biomarker market during the forecast period.
The global neurological biomarker market is segmented on the basis of product, application, and end user. Based on product, the market is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, genomics biomarker held the largest share of the market; moreover, the market for the same is expected to grow at the fastest CAGR during the forecast period.Based on application, the neurological biomarker marketis segmented into Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others.On the basis of enduser, the neurological biomarker market has been segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations.
The Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), European Federation of Pharmaceuticals Industries Associations, European Medical Association, Biomarkers Biospecimen and Data Repository, Global Burden of Disease, and Boston University School of Medicineare a few of the essential secondary sources referred to while preparing this report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the neurological biomarker market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global neurological biomarker market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Key Topics Covered:
1. Introduction
2. Neurological Biomarker Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Neurological Biomarker Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific- PEST Analysis
4.2.4 Middle East and Africa - PEST Analysis
4.2.5 South & Central America
4.3 Expert Opinion
5. Neurological Biomarker Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Neurological Diseases
5.1.2 Growing Focus on Neurological Biomarker Research
5.2 Key Market Restraints
5.2.1 Concerns Associated with Biomarkers
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trends
5.4.1 The Rising Trend of Precision/Personalized Healthcare
5.5 Impact analysis
6. Neurological Biomarker Market - Global Analysis
6.1 Global Neurological Biomarker Market Revenue Forecast And Analysis
6.2 Global Neurological Biomarker Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Neurological Biomarker Market Analysis- by Product
7.1 Overview
7.2 Neurological Biomarker Market Share, By Product, 2019 & 2027 (%)
7.2.1 Neurological Biomarker Market Revenue and Forecasts to 2027, By Product(US$ Mn)
7.3 Proteomics Biomarker
7.3.1 Overview
7.3.2 Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Genomics Biomarker
7.4.1 Overview
7.4.2 Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
7.5.1 Overview
7.5.2 Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
7.6.1 Overview
7.6.2 Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Neurological Biomarker Market Analysis- by Application
8.1 Overview
8.2 Neurological Biomarker Market Share, By Application, 2019 & 2027 (%)
8.2.1 Neurological Biomarker Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Alzheimer's Disease
8.3.1 Overview
8.3.2 Alzheimer's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson's Disease
8.4.1 Overview
8.4.2 Parkinson's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
8.5.1 Overview
8.5.2 Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
8.6.1 Overview
8.6.2 Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
8.7.1 Overview
8.7.2 Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Neurological Biomarker Market Analysis- by End User
9.1 Overview
9.2 Neurological Biomarker Market Share, By End User, 2019 & 2027 (%)
9.2.1 Neurological Biomarker Market Revenue and Forecasts to 2027, By End User (US$ Mn)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
9.4.1 Overview
9.4.2 Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
9.5.1 Overview
9.5.2 Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Neurological Biomarker Market Analysis And Forecasts To 2027 - Geographical Analysis
10.1 North America: Neurological Biomarker Market
10.2 Europe: Neurological Biomarker Market
10.3 Asia Pacific: Neurological Biomarker Market
10.4 Middle East and Africa: Neurological Biomarker Market
10.5 South and Central America: Neurological Biomarker Market
11. Impact of COVID-19 Pandemic on Global Neurological Biomarker Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Thermo Fisher Scientific Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott
13.3 Myriad Genetics, Inc.
13.4 Bio-Rad Laboratories Inc.
13.5 QIAGEN
13.6 Banyan Biomarkers, Inc
13.7 Immunarray Pvt. Ltd.
13.8 Quest Diagnostics Incorporated
13.9 Perkin Elmer, Inc.
13.10 MERCK KGaA
14. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/4pwhp
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.